Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged between 20 and 75 years~2. Subjects who had experienced a minimum three-month history of main symptom(heartburn and regurgitation)~3. Subjects were to have normal esophagus confirmed by endoscopy within 14 days prior to randomization~4. Subjects who is able to understand and follow the instructions and is willing to participate throughout the entire study~5. Subjects who voluntarily signed written informed consent form~6. Subjects who agreed to use medically acceptable contraceptives during the period of study~7. Subjects who had experienced heartburn and regurgitation within 7 days before randomization. Entry into study also required that patients had experienced at least mild upper gastrointestinal symptoms on at least 2 days/week or at least moderate upper gastrointestinal symptoms on at least 1 day/week~Exclusion Criteria:~1. Subjects who cannot undergo EGD~2. Subjects who have esophageal stenosis, ulcer stenosis, gastroesophageal varices, Barrett's esophagus, active gastric ulcer, gastrointestinal bleeding or malignant tumor confirmed by EGD~3. Subjects who have erosive esophagitis, acute upper gastrointestinal bleeding, gastric ulcers or duodenal ulcers, acute erosive gastritis within 2 months before randomization. Subjects with gastric or duodenal erosions are allowed to be included.~4. Subjects who have warning symptoms of malignant gastrointestinal tract such as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody stool~5. Subjects with eosinophilic esophagitis~6. Subjects diagnosed with functional dyspepsia, primary esophageal motility disorder, IBS, IBD, etc. or with suspected IBS in the last 3 months~7. Subjects who have a history of gastric acid suppression surgery or upper gastrointestinal, esophageal surgery~8. Subjects who have bipolar disorder, anxiety disorder, panic disorder, somatoform disorder, personality disorder and psychiatric disorders.~9. Subjects who are taking antipsychotic drugs, antidepressants or antianxiety medications~10. Subjects who should continuously administer NSAIDs during the trial.~11. Pregnant or lactating women~12. Subjects with a history of clinically significant hepatic, renal, cardiovascular, respiratory, endocrine and CNS system disorder~13. Subjects with a history of hypersensitivity to the active ingredient or excipients of the study drug, etc.~14. Subjects who participated in the other clinical trial within 4 weeks prior to randomization

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CJ-12420 50mg (Type: EXPERIMENTAL): CJ-12420 50 mg, tablet, once daily, oral administration for up to 4 weeks
- CJ-12420 100mg (Type: EXPERIMENTAL): CJ-12420 100 mg, tablet, once daily, oral administration for up to 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, tablet, once daily, oral administration for up to 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).